TipiracilHCl , 98% , 183204-72-0
Synonym(s):
5-Chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidinedione hydrochloride;TPI hydrochloride
| Pack Size | Price | Stock | Quantity |
| 100mg | RMB70.40 | In Stock |
|
| 250mg | RMB104.80 | In Stock |
|
| 1g | RMB261.60 | In Stock |
|
| 5g | RMB914.40 | In Stock |
|
| 25g | RMB2743.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 245℃ (decomposition) |
| storage temp. | 2-8°C |
| solubility | DMSO (Slightly, Heated), Water (Slightly) |
| form | powder |
| color | white to beige |
| Stability: | Hygroscopic |
Description and Uses
Tipiracil (TPI) is a potent and competitive inhibitor of thymidine phosphorylase (TPase) with an IC50 value of 35 nM for human placental TPase. It is selective for TPase over other pyrimidine-metabolizing enzymes (IC50s = >1 mM for UPase, OPRTase, TK, and DPDase). TPI inhibits the phosphorolysis and degradation of trifluorothymidine , a cytotoxic nucleoside, in human breast and colon carcinoma tumor samples. Oral administration of TPI (12.5-50 mg/kg) enhances the anti-tumor activity of trifluorothymidine in a mouse AZ-521 stomach cancer xenograft model. Formulations containing TPI have been used for the treatment of metastatic colorectal cancer.
Tipiracil Hydrochloride serves as a treatment for metastatic colorectal cancer (mCRC). A thymidine phosphorylase inhibitor.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315-H319 |
| Precautionary statements | P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313 |
